Evidence map›Paper›PMID 34571277›Full record

ReviewDrug discovery today2022

Agonist antibody discovery: Experimental, computational, and rational engineering approaches.

John S Schardt, Harkamal S Jhajj, Ryen L O'Meara, Timon S Lwo, Matthew D Smith, Peter M Tessier

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Drug discovery today, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Building Representation Learning Models for Antibody Comprehension.Cold Spring Harbor perspectives in biology · 2024
    Review
  9. Review
  10. Article
  11. Cryo-electron microscopy-based drug design.Frontiers in molecular biosciences · 2024
    Review
  12. Article
  13. Review
  14. Joined at the hip: The role of light chain complementarity determining region 2 in antibody self-association.Proceedings of the National Academy of Sciences of the United States of America · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

John S SchardtDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Harkamal S JhajjDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Ryen L O'MearaDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Timon S LwoDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Matthew D SmithDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Peter M TessierDepartment of Chemical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pharmaceutical Sciences, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI 48109, USA; Biointerfaces Institute, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address: ptessier@umich.edu.
BioSurfaces (United States) · USUniversity of Michigan–Ann Arbor · US

Funding

Design and Evolution of Polyvalent Domain Antibodies Specific for Tau AggregatesRF1AG059723 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KANE, RAVI S., TESSIER, PETER M · 2018 to 2022
$2.4M
Structure-guided antibody targeting of pre-selected epitopes in amyloidogenic aggregatesR35GM136300 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI TESSIER, PETER M · 2020 to 2024
$1.5M
Administrative Supplement: Activity-based Discovery and OptimizationF32GM137513 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHARDT, JOHN SAMUEL · 2020 to 2022
$141k
NIA NIH HHS RF1 AG059723NIGMS NIH HHS F32 GM137513NIGMS NIH HHS R35 GM136300
6 · The paper itself

Abstract

Agonist antibodies that activate cellular signaling have emerged as promising therapeutics for treating myriad pathologies. Unfortunately, the discovery of rare antibodies with the desired agonist functions is a major bottleneck during drug development. Nevertheless, there has been important recent progress in discovering and optimizing agonist antibodies against a variety of therapeutic targets that are activated by diverse signaling mechanisms. Herein, we review emerging high-throughput experimental and computational methods for agonist antibody discovery as well as rational molecular engineering methods for optimizing their agonist activity.

Indexed as

Drug DiscoveryTechnology, PharmaceuticalAntibodies, MonoclonalBiological ProductsComputer SimulationHumansImmunologic FactorsSignal TransductionAntibodies, MonoclonalBiological ProductsImmunologic FactorsActivationAgonistAntibodyBiologicDiscoveryEngineeringFunction-based screeningHigh throughputmAbsignaling

Identifiers

PMID34571277
PMCPMC8714685
OpenAlexW3204202206

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.